about
Clinical trial design and selected drug safety issues for antibiotics used to treat community-acquired pneumoniaCentral nervous system tuberculosisPrevalence of the prescription of potentially interacting drugsGender analysis of moxifloxacin clinical trialsTreatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical SignificanceTendon Injury and Fluoroquinolone Use: A Systematic Review.A rare case of ciprofloxacin-induced bilateral rupture of the Achilles tendon.Ciprofloxacin-induced tendinopathy of the gluteal tendons.Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.Bacteriuria amongst pregnant women in the Buea Health District, Cameroon: prevalence, predictors, antibiotic susceptibility patterns and diagnosisCumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy.Drug-resistant tuberculosis: emerging treatment options.Comparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: an analysis of national representative claims databaseThe management of mid-portion achilles tendinopathy with astym® and eccentric exercise: a case report.Alternative approaches to conventional treatment of acute uncomplicated urinary tract infection in women.Tigecycline does not prolong corrected QT intervals in healthy subjects.Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Nature versus nurture in two highly enantioselective esterases from Bacillus cereus and Thermoanaerobacter tengcongensis.Embryotoxic and teratogenic effects of norfloxacin in pregnant female albino ratsImmediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature.Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016.Fluoroquinolone resistance in campylobacter.Quinolones: review of psychiatric and neurological adverse reactions.Drug-induced photosensitivity: culprit drugs, management and prevention.Cardiovascular and metabolic safety profiles of the fluoroquinolones.Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review.Fluoroquinolone-induced liver injury: three new cases and a review of the literature.Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review.Cardiovascular disease: primary prevention, disease modulation and regenerative therapy.The role of besifloxacin in the treatment of bacterial conjunctivitis.Pathogen-induced secretory diarrhea and its prevention.Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review.Quinolone antibiotics and suicidal behavior: analysis of the World Health Organization's adverse drug reactions database and discussion of potential mechanisms.Effects of concurrent perioperative use of marbofloxacin and cimicoxib or carprofen in dogs.An open study of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis: efficacy, complications and outcome.A seizure attributed to ofloxacine in a woman undergoing detoxification for alcohol dependence.Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics.
P2860
Q24654370-50AF0CD3-EBF4-471A-96A4-038B02806505Q28237650-CED81282-4692-4B32-8A9E-9CC379C0C29CQ28534352-4222E2F7-EC71-427A-95C3-2ABCD63EEF88Q28538319-3D175858-82E2-4C07-B778-3CA55E3248E6Q33494958-01330559-B58D-482F-B61D-7F9DD142B413Q33653994-06B287FB-E802-4551-BC68-59B2E40965B4Q34359994-988D7A59-BDBF-4C6F-ABB9-DCDBE3C52C1DQ34526517-54B0377B-EB0A-4ABA-80D0-C74BCE2BCF3FQ34546356-93F7A741-799F-4F92-87C1-1C91E5112886Q34941542-AEF1EFA1-E0C3-46B6-84A3-91198B0FDC0FQ34970599-71BD0C5B-C9B4-4092-A14C-EB29709FF852Q35547748-3B407BE8-DFA6-4CA4-9F8A-BA740BF27D07Q35683967-0F5C257E-86EA-4871-A0CF-ABB59BED324BQ36153920-2975F70C-DE30-4C24-A801-333493E73724Q36509843-BB7728BC-2D32-4779-81AB-5615E1E88382Q36754301-B92DBDCE-A644-4E15-AEA3-AA596E578F85Q36757583-D959586C-6C00-421D-9E1B-495FE571A626Q36886266-FF0D4DD2-0AF3-407E-8294-36B593870E54Q37052814-D9A4A825-577C-4D6E-AB5E-5860A4E1B916Q37124090-D864BA4A-5056-40A9-8F9A-532D52B17EC9Q37274933-46644BF5-D365-4A1A-9A65-590B41301923Q37594654-1C786B64-B0FF-4026-BE49-52FCCFE6F822Q37710230-D855C4DE-999C-4E8C-8B1D-9B5529144D3AQ37724289-92929DCF-47CC-4BD1-8E20-53DEA803E211Q37764099-1D87309F-F39F-4FDB-803D-B431DD1ED938Q37876399-B40C3F1B-BDFD-4105-8CB5-482B8ECB3217Q37924276-463AB92E-E2AE-49E5-A884-254D3B044FB5Q37940543-C88FD720-1E78-4855-8C6E-51D2302C5A5EQ37964751-D98660FD-7F6E-46BC-BC27-99581CC0C6F0Q37975927-56C863DC-2E5B-49B8-9FBE-3B8A6F9B1AD6Q37982661-8CDBDFAB-45CC-4323-B8C5-CDCE9B5FC7A4Q38047290-293F89E7-10C6-4937-B139-2F2261FE01F0Q38190827-41A5D3EE-19F3-49B7-8F30-9FB482DD5126Q38912737-6012B58E-9717-4377-B20D-9C39FB31B3CEQ40108685-8BE39495-1CBE-4B7A-8AE0-156E56F62983Q40782394-A3A8FAEF-E165-4507-B7FB-B20144003394Q40826392-8CAAD27B-A93D-42F1-9FCE-C675A5B36D4AQ42644383-930D8B01-A276-4CFB-8BCF-EE96148F2178Q42922049-ABE5B6E5-8480-4FBC-837B-ECC5AA04194CQ44213464-03947060-353C-469F-819B-24B99527B32B
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Safety concerns with fluoroquinolones
@ast
Safety concerns with fluoroquinolones
@en
Safety concerns with fluoroquinolones
@nl
type
label
Safety concerns with fluoroquinolones
@ast
Safety concerns with fluoroquinolones
@en
Safety concerns with fluoroquinolones
@nl
prefLabel
Safety concerns with fluoroquinolones
@ast
Safety concerns with fluoroquinolones
@en
Safety concerns with fluoroquinolones
@nl
P356
P1476
Safety concerns with fluoroquinolones
@en
P2093
Allana J Mehlhorn
Dana A Brown
P304
P356
10.1345/APH.1K347
P407
P577
2007-11-01T00:00:00Z